- Home
- VLYPO vs LYEL Comparison
VLYPO vs LYEL Comparison
Compare VLYPO & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLYPO
- LYEL
- Stock Information
- Founded
- VLYPO N/A
- LYEL 2018
- Country
- VLYPO United States
- LYEL United States
- Employees
- VLYPO 3732
- LYEL N/A
- Industry
- VLYPO Major Banks
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- VLYPO Finance
- LYEL Health Care
- Exchange
- VLYPO Nasdaq
- LYEL Nasdaq
- Market Cap
- VLYPO N/A
- LYEL 207.7M
- IPO Year
- VLYPO N/A
- LYEL 2021
- Fundamental
- Price
- VLYPO $24.69
- LYEL $9.69
- Analyst Decision
- VLYPO
- LYEL Sell
- Analyst Count
- VLYPO 0
- LYEL 2
- Target Price
- VLYPO N/A
- LYEL $15.00
- AVG Volume (30 Days)
- VLYPO N/A
- LYEL 232.0K
- Earning Date
- VLYPO N/A
- LYEL 08-06-2025
- Dividend Yield
- VLYPO N/A
- LYEL N/A
- EPS Growth
- VLYPO N/A
- LYEL N/A
- EPS
- VLYPO N/A
- LYEL N/A
- Revenue
- VLYPO N/A
- LYEL $65,000.00
- Revenue This Year
- VLYPO N/A
- LYEL N/A
- Revenue Next Year
- VLYPO N/A
- LYEL N/A
- P/E Ratio
- VLYPO N/A
- LYEL N/A
- Revenue Growth
- VLYPO N/A
- LYEL N/A
- 52 Week Low
- VLYPO N/A
- LYEL $7.65
- 52 Week High
- VLYPO N/A
- LYEL $38.40
- Technical
- Relative Strength Index (RSI)
- VLYPO 47.29
- LYEL 51.52
- Support Level
- VLYPO $24.69
- LYEL $8.46
- Resistance Level
- VLYPO $24.80
- LYEL $9.84
- Average True Range (ATR)
- VLYPO 0.22
- LYEL 0.86
- MACD
- VLYPO -0.03
- LYEL -0.05
- Stochastic Oscillator
- VLYPO 39.68
- LYEL 47.00
About VLYPO Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B
Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.